Clene Inc (CLNN) Stock Price, Quote & News

Company Profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; comp...

Industry: Packaged Foods

Sector: Consumer Defensive

Phone: 801 676 9695

Website: clene.com

Address:

6550 South Millrock Drive, Suite G50, Salt Lake City, United States

ransoms2121212 Dec. 25 at 2:46 PM

$CLNN All I want for Christmas is an Accelerated Approval

1 · Reply

neuroinvestor3 Dec. 24 at 1:17 PM

$CLNN is anyone taking CNM-Au8 or know anyone that is?

2 · Reply

SuperGreenToday Dec. 24 at 12:29 PM

$CLNN

0 · Reply

ransoms2121212 Dec. 23 at 11:21 PM

$CLNN @Mulhollandr I remain very bullish on the stock & potential (& confident these sales are to harvest tax loss offsetting gains on Metsera given gap between current valuation & spac valuation). That said, based on previous (& numerous) professional exchanges (about transactions in other, unrelated tickers), if I were a betting man (& I am), I would bet Chidozie / Sym is going to liquidate the entire position outlined in 12.05 filing....

1 · Reply

biotrade123 Dec. 23 at 8:20 PM

$CLNN will it hold 6?

2 · Reply

Mulhollandr Dec. 23 at 3:13 PM

$CLNN anyone else testing the waters? I’ve picked up 2k shares in the past week that are all currently sitting green. :)

2 · Reply

josh77 Dec. 23 at 3:39 AM

$CLNN 1. Clinical Trial Progress & Data Readouts Clene’s lead asset is CNM-Au8, a nanotherapeutic being developed for neurodegenerative diseases like ALS and MS. In 2026, investors will be watching for: New or updated clinical trial results Long‑term extension data Any signs of efficacy strong enough to support regulatory filings This is the single biggest driver of valuation for a company like CLNN. 🏛️ 2. Regulatory Pathway (FDA/EMA) If CLNN produces positive data, the next steps could include: FDA meetings (Type B or pre‑NDA) Fast Track or Breakthrough Therapy updates Potential NDA submission timelines Regulatory clarity is a major catalyst for biotech stocks.

0 · Reply

neuroinvestor3 Dec. 22 at 3:47 PM

$CLNN Is Ugwumba gonna sell the rest of his 390K shares?

1 · Reply

ransoms2121212 Dec. 19 at 7:00 PM

$CLNN

1 · Reply

Mulhollandr Dec. 19 at 12:21 AM

$CLNN “insider” sell was previously announced with the form 144 that was filed on 12/5. This filing is from a legacy holder, not a current executive, a current board member, a scientific lead, or someone with real-time operational insight. Just some accounting as others have mentioned. But if there is a dip…I’m ready🤑

1 · Reply

Clene to Present at the Emerging Growth Conference

Dec 3, 2025, 8:00 AM EST - 22 days ago

Clene Announces Statistically Significant ALS Biomarker Results Supporting Accelerated Approval Pathway for CNM-Au8®

Dec 2, 2025, 5:39 PM EST - 23 days ago

Clene to Provide CNM-Au8® ALS Program Update

Nov 20, 2025, 8:00 AM EST - 5 weeks ago

Clene to Participate at the Benchmark 14th Annual Discovery One-on-One Investor Conference

Nov 13, 2025, 8:00 AM EST - 6 weeks ago

Clene Reports Third Quarter 2025 Financial Results and Recent Operating Highlights

Oct 15, 2025, 8:30 AM EDT - 2 months ago

Clene to Participate in a Panel Discussion at the Maxim Growth Summit

Sep 25, 2025, 8:00 AM EDT - 3 months ago

Clene Presents New Clinical Data at ECTRIMS 2025 Meeting Demonstrating CNM-Au8® Improves Brain Energy Metabolism in Multiple Sclerosis Patients

Sep 4, 2025, 8:30 AM EDT - 4 months ago

Clene Presents Preclinical Data Supporting CNM-Au8® for the Treatment of Parkinson's Disease

Sep 2, 2025, 8:00 AM EDT - 4 months ago

Clene to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 8:38 AM EDT - 4 months ago

Clene Reports Second Quarter 2025 Financial Results and Recent Operating Highlights

Aug 5, 2025, 8:30 AM EDT - 5 months ago

Clene to Present at the Canaccord 45th Annual Growth Conference

Jun 30, 2025, 8:00 AM EDT - 6 months ago

Clene Provides Regulatory Update Following Constructive FDA Type-C Meeting on Neurofilament Biomarker Analysis Plan and Confirms Two Additional FDA Meetings

Jun 9, 2025, 9:00 AM EDT - 7 months ago

Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

May 7, 2025, 8:00 AM EDT - 8 months ago

Clene Reports First Quarter 2025 Financial Results and Recent Operating Highlights

Apr 1, 2025, 8:30 AM EDT - 9 months ago

Clene to Present at the Jones Healthcare and Technology Innovation Conference

Mar 24, 2025, 8:00 AM EDT - 9 months ago

Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights

Mar 12, 2025, 8:00 AM EDT - 10 months ago

Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Mar 6, 2025, 8:30 AM EST - 10 months ago

Clene to Present at the 37TH Annual Roth Conference

Feb 27, 2025, 9:15 AM EST - 10 months ago

Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Feb 25, 2025, 8:00 AM EST - 10 months ago

Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction

Dec 10, 2024, 8:30 AM EST - 1 year ago

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Clene Announces $7.3 Million Registered Direct Offering and Concurrent Private Placements Priced at Market Under Nasdaq Rules

Sep 16, 2024, 8:30 AM EDT - 1 year ago

Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

IBN Announces Latest Episode of The BioMedWire Podcast featuring Rob Etherington, CEO of Clene Inc.

Aug 7, 2024, 8:23 AM EDT - 1 year ago

Clene Reports Second Quarter 2024 Financial Results and Recent Operating Highlights

Jul 11, 2024, 9:00 AM EDT - 1 year ago

Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS

Jul 9, 2024, 8:00 AM EDT - 1 year ago

Clene Announces 1-for-20 Reverse Stock Split

Jun 24, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at H.C. Wainwright's 5th Annual Neuro Perspectives Virtual Conference

Jun 21, 2024, 7:09 AM EDT - 1 year ago

Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome

Jun 18, 2024, 7:00 AM EDT - 1 year ago

Clene Presents Extended Survival Data Through 3.5 Years and New NfL Responder Results with CNM-Au8® 30 mg Treatment from the HEALEY ALS Platform Trial Open Label Extension at the 2024 ENCALS Meeting

May 28, 2024, 7:30 AM EDT - 1 year ago

Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)

May 14, 2024, 8:00 AM EDT - 1 year ago

Clene to Present at Upcoming May Conferences

May 8, 2024, 8:00 AM EDT - 1 year ago

Clene Reports First Quarter 2024 Financial Results and Recent Operating Highlights

Apr 16, 2024, 4:01 PM EDT - 1 year ago

Evidence for Clene's CNM-Au8® as a Treatment for Repair and Remyelination in Multiple Sclerosis Presented in the Emerging Science Session at the 2024 American Academy of Neurology Annual Meeting

Mar 15, 2024, 8:00 AM EDT - 1 year ago

Clene Announces Peer-Reviewed Publication Characterizing the Protein Corona of the Investigational Neurodegenerative Disease Drug, CNM-Au8®

Mar 13, 2024, 8:00 AM EDT - 1 year ago

Clene Reports Full Year 2023 Financial Results and Recent Operating Highlights

Feb 29, 2024, 8:00 AM EST - 1 year ago

Clene Presents Clinical Results of CNM-Au8® 30mg Treatment From Visionary-MS Trial Long-Term Extension at Annual ACTRIMS Forum 2024

Dec 21, 2023, 11:25 AM EST - 2 years ago

Clene says FDA finds ALS drug data not enough for accelerated nod

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Reports Reduction in Biomarker Plasma Neurofilament Light (NfL) Levels and Improved Survival With CNM-Au8® Treatment From HEALEY ALS Platform Trial Long-Term Open Label Extension

Dec 21, 2023, 7:00 AM EST - 2 years ago

Clene Provides Update on ALS Clinical Development Meeting With FDA

Dec 14, 2023, 8:36 AM EST - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Brain Target Engagement In Neurodegenerative Diseases

Nov 7, 2023, 8:00 AM EST - 2 years ago

Clene Reports Third Quarter 2023 Financial Results and Operating Highlights

Oct 5, 2023, 10:00 AM EDT - 2 years ago

National Institutes of Health Awards $45.1 Million NINDS Grant for CNM-Au8® Study in ALS

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action

Sep 25, 2023, 4:00 PM EDT - 2 years ago

Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference

Sep 25, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significant Long-Term Survival Improvement From CNM-Au8 Treatment in HEALEY ALS Platform Trial Compared to PRO-ACT Historical Controls

Aug 30, 2023, 8:20 AM EDT - 2 years ago

Clene to Present at Upcoming September Conferences

Aug 29, 2023, 7:00 AM EDT - 2 years ago

Clene Reports Significantly Improved Survival Benefit of 19.3 Months and Significantly Delayed Clinical Worsening in Rescue-Als Open-Label Extension Two Year Follow-Up

Aug 14, 2023, 8:00 AM EDT - 2 years ago

Clene Reports Second Quarter 2023 Financial Results and Operating Highlights

ransoms2121212 Dec. 25 at 2:46 PM

$CLNN All I want for Christmas is an Accelerated Approval

1 · Reply

neuroinvestor3 Dec. 24 at 1:17 PM

$CLNN is anyone taking CNM-Au8 or know anyone that is?

2 · Reply

SuperGreenToday Dec. 24 at 12:29 PM

$CLNN

0 · Reply

ransoms2121212 Dec. 23 at 11:21 PM

1 · Reply

biotrade123 Dec. 23 at 8:20 PM

$CLNN will it hold 6?

2 · Reply

Mulhollandr Dec. 23 at 3:13 PM

$CLNN anyone else testing the waters? I’ve picked up 2k shares in the past week that are all currently sitting green. :)

2 · Reply

josh77 Dec. 23 at 3:39 AM

0 · Reply

neuroinvestor3 Dec. 22 at 3:47 PM

$CLNN Is Ugwumba gonna sell the rest of his 390K shares?

1 · Reply

ransoms2121212 Dec. 19 at 7:00 PM

$CLNN

1 · Reply

Mulhollandr Dec. 19 at 12:21 AM

1 · Reply

LXP Dec. 18 at 10:30 PM

$CLNN big sale of 200k insider shares over 2wks. Hate to see this

3 · Reply

biotrade123 Dec. 18 at 5:46 PM

$CLNN looks like this is going to trade in this rage 6-7 for a while?

3 · Reply

Mulhollandr Dec. 18 at 4:02 PM

$CLNN I called Morgan to see what he can share about the Schwab shenanigans. Let’s see if he gets back to me.

2 · Reply

neuroinvestor3 Dec. 16 at 12:49 PM

$CLNN what can/will Clene IR do to allow schwab and others to remove the electronic trading impediment?

1 · Reply

ransoms2121212 Dec. 15 at 10:10 PM

$CLNN To @Ravery credit, the short interest has spiked over the past few days

1 · Reply

ransoms2121212 Dec. 15 at 9:55 PM

$CLNN Canaccord notes that the company has “cash runway into 2q26” I believe they are involved with the ATM—big if the above is true

1 · Reply

neuroinvestor3 Dec. 15 at 6:45 PM

$CLNN I think we are seeing selling because Schwab and some others have tagged Clene as being "subject to questionable trading practices." this is BS.

0 · Reply

ransoms2121212 Dec. 15 at 5:06 PM

$CLNN new CG equity research....still very bullish

3 · Reply

neuroinvestor3 Dec. 15 at 3:23 PM

$CLNN FYI -still can't trade shares on Schwab without calling them first. Are there shenanigans occurring? WTF?

1 · Reply

Scandal2024 Dec. 13 at 4:45 PM

$CLNN Any thoughts on the tender offer?

4 · Reply

Mulhollandr Dec. 12 at 7:19 PM

$CLNN ✌🏻had to run to Aruba. See y’all next week.

1 · Reply

Ravery Dec. 12 at 1:52 PM

$CLNN Does Rob realize that balance sheet uncertainty is a stock price killer for clinical bios? Radio silence on the matter just leaves a huge dark cloud over the shares. However they plan to shore up the BS, just be transparent with investors.

1 · Reply

Market Cap	65.72M
Revenue (ttm)	340,000.00
Net Income (ttm)	-39.40M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-11,588.24%
Debt to Equity Ratio	-0.37

Volume	17,100
Avg Vol	191,884
Day's Range	N/A - N/A
Shares Out	10.33M
Stochastic %K	36%
Beta	0.79
Analysts	Strong Sell
Price Target	$31.86